|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Focalin
gptkb:Focalin_XR
|
|
gptkbp:activities
|
reuptake inhibitor
|
|
gptkbp:affects
|
norepinephrine levels
dopamine levels
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:2001
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Focalin
|
|
gptkbp:class
|
central nervous system stimulant
|
|
gptkbp:clinical_trial
|
ADHD treatment studies
cognitive enhancement studies
|
|
gptkbp:contraindication
|
gptkb:sneaker
heart problems
hyperthyroidism
|
|
gptkbp:dosage_form
|
2.5 to 10 mg
|
|
gptkbp:duration
|
4 to 6 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
dexmethylphenidate hydrochloride
|
|
gptkbp:future_plans
|
abuse
dependence
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
dexmethylphenidate
|
|
gptkbp:ingredients
|
C14 H19 N O2
|
|
gptkbp:interacts_with
|
antidepressants
MAO inhibitors
antihypertensives
|
|
gptkbp:is_available_in
|
capsule form
tablet form
|
|
gptkbp:is_available_on
|
extended-release formulation
|
|
gptkbp:is_monitored_by
|
blood pressure
heart rate
growth in children
|
|
gptkbp:is_used_by
|
gptkb:Person
adults
|
|
gptkbp:is_used_for
|
treatment of ADHD
|
|
gptkbp:lifespan
|
2.2 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:Novartis
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:premiered_on
|
1 to 2 hours
|
|
gptkbp:related_to
|
gptkb:drug
|
|
gptkbp:requires
|
prescription only
|
|
gptkbp:safety_features
|
Category C
|
|
gptkbp:side_effect
|
anxiety
nausea
decreased appetite
insomnia
dry mouth
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:suitable_for
|
pregnant women
nursing mothers
patients with a history of substance abuse
|
|
gptkbp:symptoms
|
gptkb:historical_event
fatigue
sleep disturbances
|
|
gptkbp:tradition
|
may develop with prolonged use
|
|
gptkbp:type_of
|
2201-15-4
|